DaVita Inc. Q2 2026 Earnings Call Summary
DaVita reported Q2 2026 updates on dialysis operations, citing improved patient mortality and a Medicare bundle shift that reduced reliance on OTC phosphate binders by over 50%. Revenue per treatment fell sequentially. DaVita reconfirmed 2026 adjusted operating income guidance of $2.2B and expects 2026 treatment growth at the top of 25-50 bps. FDA approval of NIPRO expanded HD dialyzers may improve supply.
How this was made
The 30-second read
Why it matters
Traders can update models using reconfirmed 2026 adjusted operating income guidance ($2.2B) and the updated 2026 treatment growth and RPT assumptions, while monitoring the 2027 ESRD proposed rule uncertainty and the timing of expanded HD financial impact (likely 2028).
Market read
The article is a decision-oriented earnings call summary with concrete guidance inputs and a catalyst timeline that can drive near-term positioning and longer-dated expectations.
What to watch
The call highlights missed treatments and fewer patient admits from closed competitor clinics, which could indicate competitive and operational pressures that may not fully reverse even if mortality improves.
Background
DaVita’s Q2 2026 earnings call summary focuses on dialysis clinical outcomes, Medicare bundle effects on phosphate binders, and a strategic pivot toward middle molecule clearance via expanded hemodialysis.
Ticker impact
DaVita reconfirmed full-year 2026 adjusted operating income guidance of $2.2B and updated 2026 treatment growth and RPT outlook on the call.
Likely modest post-call repricing around the reconfirmed $2.2B and the slightly negative H2 RPT growth implication, with upside tied to expanded HD economics materializing in 2028.
The article provides specific, decision-relevant guidance inputs (2026 AOI $2.2B, Q3 to Q4 IKC timing, 2026 treatment growth top-end of 25-50 bps, and 1-2% RPT growth implying negative YoY in 2H). It also flags a key uncertainty (2027 ESRD proposed rule) and a catalyst timeline (expanded HD financial impact likely insignificant until 2028).
Market effects
Dialysis-provider read-through on Medicare dialysis bundle dynamics, phosphate binder economics, and adoption of expanded hemodialysis technology.
Primarily US healthcare reimbursement and provider operations, with limited direct regional spillover beyond US dialysis markets.
Low direct global relevance; technology supply and FDA approval may affect US treatment availability and economics.
Counterpoint
The expanded HD catalyst is framed as financially insignificant until 2028, so near-term valuation may be more constrained by RPT mix headwinds and cost inflation than by the longer-dated mortality benefit.
Key entities
- companyDaVita Inc.
US dialysis provider reconfirming 2026 adjusted operating income guidance and outlining expanded hemodialysis and IKC growth drivers.
- companyElara Caring
Home health services provider in which DaVita made a $200 million minority investment that closed in July.
- companyNIPRO
FDA-approved supplier of new expanded HD dialyzers expected to improve market supply and economics.
- regulatorCMS
Reduced its estimate for phosphate binder spend by nearly $500 million, affecting policy-driven economics.
